[Improved osseointegration and periprosthetic bone volume around cementless metal implants under bisphosphonate treatment].
OBJECTIVE
The effects of a systemic treatment with the bisphosphonate ibandronate on osseointegration of uncoated and hydroxyapatite-coated titanium implants and on periprosthetic bone volume have been evaluated and the dosage of medication had to be defined.


METHODS
We used an animal model of the rat, the animals were assigned to three treatment groups receiving 1 microg, 5 microg and 25 microg/kg body weight and one control group receiving NaCl 0.9%. An uncoated and a hydroxyapatite-coated titanium rod were inserted into the medullary canal of the femur. After 28 days the specimens were harvested and histomorphometric evaluation revealed extend of osseointegrated implant surface and changes of periprosthetic bone volume.


RESULTS
Treatment groups receiving 5 microg and 25 microg ibandronate showed significant improvement of osseointegrated implant surface compared to the control group. Enhancement of periprosthetic bone volume was revealed in all treatment groups but only application of 25 microg ibandronate was significantly improved compared to the control group.


CONCLUSIONS
A minor dose of 1 microg ibandronate is not effective to improve osseointegration. A high dosed bisphosphonate treatment with 5 microg or 25 microg ibandronate is potent to improve osseointegrated implant surface significantly compared to an untreated control in both uncoated and hydroxyapatite-coated titanium implants and to enhance periprosthetic bone volume. By that, improved secondary stability and prolonged survival time of cementless metal implants can be expected.
Eberhardt
C
C
Orthopädische Universitäts- und Poliklinik Frankfurt. C.Eberhardt@friedrichsheim.de
Raussen
W
W
Thiemann
S
S
Schwarz
M
M
Bauss
F
F
Kurth
A A
AA
D000818:Animals; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D002484:Cementation; D004164:Diphosphonates / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005269:Femur / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology* / Q000601:surgery*; D007593:Joint Instability / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control*; D009929:Organ Size / Q000187:drug effects; D016348:Osseointegration / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014025:Titanium; D016896:Treatment Outcome
D004164:Diphosphonates; D014025:Titanium